Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy

Goran Rakocevic; Ubaldo Martinez-Outschoorn; Marinos C. Dalakas

doi:10.1212/NXI.0000000000000460

Full PDF

Citation

Permissions

Make Comment

See Comments

Downloads

485

Article Figures & Data

Tables

Letters: Rapid online correspondence

Author Response: Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
Marinos C. Dalakas, Ubaldo Martinez-Outschoorn and Goran Rakocevic

Published May 04, 2018
RE: Obinutuzumab, a new anti-CD20 antibody, is active and effective in anti-MAG antibody polyneuropathy.
Chiara Briani, Andrea Visentin, Alessandro Salvalaggio, Mario Cacciavillani and Livio Trentin

Published April 16, 2018

Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

Stay timely. Submit only on articles published within the last 8 weeks.
Do not be redundant. Read any comments already posted on the article prior to submission.
200 words maximum.
5 references maximum. Reference 1 must be the article on which you are commenting.
5 authors maximum. Exception: replies can include all original authors of the article.
Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

Title *

Author Information

NOTE: The first author must also be the corresponding author of the comment.

Authors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Publishing Agreement

I, the first and corresponding author, verify that I have read the contents of the PUBLISHING AGREEMENT form. *

I, the first and corresponding author, verify my disclosures and those of my co-authors are up to date at http://submit.nn.neurology.org. *

Select only one of the three options below: *

I am an Author of this Work, and the Work was prepared on my own time - not as part of my duties as an employee.

I prepared (or cooperated in the preparation of) the Work as part of my duties as an employee, and the Work is, therefore, a "work made for hire", as defined by the United States Copyright Act of 1976, as amended.

I prepared (or participated in the preparation of) the Work as part of my official duties as an officer or employee of the United States Government.

NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Main menu

User menu

Search

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy

Citation Manager Formats

Article Figures & Data

Tables

Letters: Rapid online correspondence

Plain text

Vertical Tabs

You May Also be Interested in

Topics Discussed

Alert Me

Articles

About

Submit

Subscribers

Main menu

User menu

Search

Share

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy

Citation Manager Formats

Share

Article Figures & Data

Tables

Letters: Rapid online correspondence

Plain text

Vertical Tabs

You May Also be Interested in

Related Articles

Topics Discussed

Alert Me

Articles

About

Submit

Subscribers